Babylon Health was a London-headquartered telehealth and AI-triage company founded in 2013 by Ali Parsa, a former Goldman Sachs banker and Circle Health founder.
At its peak, Babylon ran the GP at Hand contract with the UK National Health Service, operated consumer telehealth in the United States and Rwanda, and offered an AI symptom-checker that drew controversy from clinicians and the UK Medicines and Healthcare Regulatory Agency.
The group went public on the New York Stock Exchange in October 2021 via a SPAC merger with Alkuri Global Acquisition Corp, listing under the ticker BBLN at a peak valuation of approximately $4.2 billion. The listed parent was Babylon Holdings Limited, a Jersey-incorporated company.
Babylon never reached profitability, and the post-listing period saw rapid revenue decline, multiple rounds of redundancies, and ultimately delisting from NYSE in 2023. The Jersey parent placed itself into administration in August 2023, US subsidiaries filed for Chapter 11 bankruptcy, and the UK operating businesses were sold or wound down.
Like Cazoo, Babylon is presented here as a structural failure case rather than a recommendation, because the unwind sequence is one of the most studied examples of a UK-operating, Jersey-parented, US-listed SPAC company entering distress.
Babylon Health is the canonical example of the Jersey-parent, UK-operating, US-listed corporate structure that proliferated in the 2021 SPAC window.
The choice of Jersey for the Babylon Holdings Limited parent reflects several practical advantages: Jersey company law is broadly familiar to UK practitioners, Jersey companies can be redomiciled or merged with relative ease, and Jersey-incorporated entities can list on US exchanges without the UK Listing Rules applying directly.
The trade-off is that Jersey parents fall outside Companies House visibility, although they file at the Jersey Financial Services Commission registry, which is publicly searchable.
Underneath the Jersey holding company sat Babylon Healthcare Services Limited and related UK Ltds, all of which remained subject to Companies House filings, FCA Senior Managers and Certification Regime where relevant, and Care Quality Commission regulation for clinical services.
When the SPAC unwound, the bifurcated structure forced parallel proceedings: a Jersey-law administration of the parent under the Bankruptcy (Desastre) Law, US Chapter 11 filings by US subsidiaries to protect operations under bankruptcy stay, and UK insolvency proceedings under the Insolvency Act 1986 for UK operating Ltds. eMed Healthcare UK acquired the GP at Hand book and other UK assets out of administration.
From a UK corporate-structure perspective, the Babylon outcome highlights why founders should think carefully about Jersey vs.
UK plc parents before pursuing US listings: Jersey offers flexibility but creates jurisdictional complexity in distress, while a UK plc structure (whether listed on the LSE Main Market or AIM) keeps insolvency proceedings consolidated within UK courts and aligns more naturally with EIS/SEIS investor expectations.
No. The original Babylon group entered administration in August 2023. Some UK assets including the GP at Hand contract were sold to eMed Healthcare UK out of administration. The Babylon brand no longer operates as a single integrated business.
Jersey-incorporated holding companies can list on US exchanges without UK Listing Rules applying directly, and Jersey company law is familiar to UK practitioners. The trade-off is jurisdictional complexity if the group enters distress.
No. Babylon listed on NYSE in October 2021 via SPAC merger with Alkuri Global Acquisition Corp under ticker BBLN. It never had a UK listing.
The Babylon unwind illustrates that Jersey-parent structures offer flexibility but create parallel insolvency proceedings in distress. UK plc structures, whether on the LSE Main Market or AIM, keep proceedings consolidated within UK courts.
